Investor Presentaiton

Mirati Therapeutics: Strong Strategic Fit || || Compelling Assets KRAZATI (adagrasib): best-in-class KRASG12C inhibitor with opportunity across multiple tumor types - Strong launch in 2L+ NSCLC; >40% share of new patients - - 1L NSCLC Phase 3 initiation by YE 2023; 3L+ CRC filing by YE 2023; 2L CRC data in 2024 MRTX1719: potential first-in-class and best-in-class potent selective PRMT5/MTA inhibitor - MTAP deleted mutations occur in -10% of cancers Phase 2 clinical trial expected to begin in first half of 2024 Early clinical pipeline features a KRAS and KRAS enabling program - KRASG12D program MRTX1133: targeting mutations implicated in key tumor types SOS1 inhibitor MRTX0902: potential for combination use with other agents targeting the MAPK/RAS pathway || Strengthens Oncology Pipeline Supports Long-term Growth Ill Bristol Myers Squibb™ - Diversifies oncology portfolio, building on BMS scientific depth in tumor intrinsic mechanisms Adds deep expertise in RAS pathway and strong track record of developing differentiated targeted molecules • Complementary to BMS existing leadership in 10 through combination opportunities ⚫ KRAZATI immediately contributes to BMS near- and medium-term growth profile Broadened pipeline enhances BMS long-term growth in oncology Not for Product Promotional Use 13

View entire presentation